This is a single-center, open-label, randomized, active-controlled study to compare DR-2011 to progesterone vaginal gel for luteal phase replacement.
This is a 2-arm, single-center, open-label, randomized, active-controlled study to compare the safety and efficacy of luteal phase replacement with DR-2011 to progesterone vaginal gel over an 18-day treatment period. Patients will also be required to use an estrogen patch during the course of the study. The overall study duration for each patient will be approximately 1½ months. Luteal phase replacement will be monitored by endometrial biopsy on Cycle Day 25 or 26. In addition, serum hormonal levels will be measured at screening and at designated times from Cycle Day 14 to 31.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Administered vaginally from Day 14 to Day 31
Administered vaginally from Cycle Day 14 to Day 31
Duramed Investigational Site
Norfolk, Virginia, United States
Adequate endometrial transformation
Time frame: Cycle Day 25 or 26
Hormone levels
Time frame: Duration of study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.